STAT June 28, 2024
Olivia Goldhill

Days after an advisory committee resoundingly voted for the Food and Drug Administration to reject MDMA as medical treatment, the founder of the company that applied for approval was ebullient. Rick Doblin, who has spent decades driving forward MDMA research, told a psychedelics conference in the Netherlands that his dream was not simply possible, but likely. There was “substantially more than a 50/50 chance” that the FDA would dismiss its advisers’ perspective and approve the first currently prohibited psychedelic come August, he said at the Interdisciplinary Conference on Psychedelic Research.

This optimism may seem misguided given the extensive criticisms and questions voiced by mental health practitioners on the advisory committee, but Doblin’s prediction is grounded in more than just a...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Mental Health, Pharma, Pharma / Biotech, Provider
Related Articles:
FDA approves Eli Lilly Alzheimer’s drug, expanding treatment options in the U.S.
STAT+: FDA approves Eli Lilly’s early Alzheimer’s treatment
Supreme Court to weigh whether the FDA was heavy-handed with flavored e-cigarette products
STAT+: How controversial was the decision by FDA’s Peter Marks to approve Sarepta’s gene therapy? Check its footnotes
FDA Finds Infectious H5N1 Bird Flu Virus In 14% Of Raw Milk Samples

Share This Article